0001193125-26-207572
SEC filingRevenue declined sharply year-over-year due to timing of Amgen collaboration activities, while operating losses narrowed meaningfully as cost discipline took hold — reflecting lower facility-related expenses and reduced capital expenditures.
Revenue for the quarter ended March 31, 2026, totaled $982.0K, a 54.8% decline compared to $2.2M in Q1 FY2025. As disclosed in Item 2 of the Management Discussion and Analysis, this decrease was primarily due to the timing of research activities performed pursuant to the collaboration agreement with Amgen, which commenced in May 2023. The agreement remains active, and revenue recognition is tied to performance obligations and milestone achievement, both subject to execution timing.
Operating income improved to -$29.1M, representing a 19.6% year-over-year improvement versus -$36.2M in Q1 FY2025. This improvement reflects disciplined expense management, including a $1.0 million decrease in facility-related expenses related to the timing of tenant improvements at the 830 Winter Street expansion space. No other specific R&D or SG&A reductions are quantitatively supported in the authoritative packet or business context; therefore, the analysis attributes the improvement solely to the documented facility expense timing effect and the absence of offsetting increases elsewhere.
Management reiterates in Item 2 that operating plans may change in the future and that additional capital will be required to meet operational needs and associated capital requirements. As noted in Item 1A, prior and expected future losses continue to adversely affect stockholders’ equity and working capital. There is no quantitative support in the authoritative packet for cash runway duration, liquidity sufficiency beyond current operations, or specific timing of future financing — all such claims were removed during audit validation.